Compare Summit Therapeutics Inc (SMMT) vs T Rowe Price Group Inc (TROW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs T Rowe Price Group Inc — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while T Rowe Price Group Inc trades at $115.59 (market cap $25.14B). The key difference: T Rowe Price Group Inc is far larger — about 2.4× Summit Therapeutics Inc's market cap, and T Rowe Price Group Inc pays a 4.43% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| SMMT | TROW | |
|---|---|---|
Market Cap | $10.48B | $25.14B |
Sector | Health | Financials |
52-Week High | $29.32 | $120.16 |
52-Week Low | $13.05 | $86.19 |
Enterprise Value | $9.90B | $21.85B |
Dividend Yield | — | 4.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
T. Rowe Price (TROW) trades at $117.61, up 0.22% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $2.52, beating expectations, and maintains strong profitability with a 28.28% net margin. Recent news highlights the launch of an actively managed crypto ETF and AUM reaching $1.89 trillion in June 2026.
The stock presents a value opportunity with a P/E of 12.59, but faces mixed analyst sentiment with a consensus Hold rating. Upside potential exists if earnings momentum continues, while risks include market volatility impacting asset management fees and competitive pressures in the investment industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About T Rowe Price Group Inc
T. Rowe Price provides asset-management services for individual and institutional investors. It offers a broad range of no-load U.S. and international stock, hybrid, bond, and money market funds. At the end of August 2022, the firm had $1.339 trillion in managed assets, composed of equity (54%), balanced (30%), fixed-income (13%), and alternatives (3%) offerings. Approximately two thirds of the company's managed assets are held in retirement-based accounts, which provides T. Rowe Price with a somewhat stickier client base than most of its peers. The firm also manages private accounts, provides retirement planning advice, and offers discount brokerage and trust services. The company is primarily a U.S.-based asset manager, deriving just under 10% of its AUM from overseas.
Read more on TROW →
